Publicaciones en las que colabora con Norberto Ortego Centeno (18)

2022

  1. IgA Vasculitis: Influence of CD40, BLK and BANK1 Gene Polymorphisms

    Journal of Clinical Medicine, Vol. 11, Núm. 19

2021

  1. Author Correction: BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis (Scientific Reports, (2021), 11, 1, (11510), 10.1038/s41598-021-91055-z)

    Scientific Reports

  2. BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis

    Scientific Reports, Vol. 11, Núm. 1

  3. Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis

    Scientific Reports, Vol. 11, Núm. 1

2017

  1. A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis

    American Journal of Human Genetics, Vol. 100, Núm. 1, pp. 64-74

  2. A combined large-scale meta-Analysis identifies COG6 as a novel shared risk locus for rheumatoid arthritis and systemic lupus erythematosus

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 1, pp. 286-294

  3. Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy

    Scientific Reports, Vol. 7

  4. Very early and early systemic sclerosis in the Spanish scleroderma Registry (RESCLE) cohort

    Autoimmunity Reviews, Vol. 16, Núm. 8, pp. 796-802

2016

  1. Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies

    Seminars in Arthritis and Rheumatism, Vol. 45, Núm. 4, pp. 391-399

2015

  1. Registry of the Spanish network for systemic sclerosis: Survival, prognostic factors, and causes of death

    Medicine (United States), Vol. 94, Núm. 43

2014

  1. Analysis of ancestral and functionally relevant CD variants in systemic lupus erythematosus patients

    PLoS ONE, Vol. 9, Núm. 11

  2. Influence of the IL17A locus in giant cell arteritis susceptibility

    Annals of the Rheumatic Diseases, Vol. 73, Núm. 9, pp. 1742-1745

2011

  1. Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label

    Arthritis Research and Therapy, Vol. 13, Núm. 4

2010

  1. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases

    Clinical and Experimental Rheumatology, Vol. 28, Núm. 4, pp. 468-476

2009

  1. Investigation of TLR5 and TLR7 as candidate genes for susceptibility to systemic lupus erythematosus

    Clinical and Experimental Rheumatology

  2. No evidence for genetic association of interferon regulatory factor 3 in systemic lupus erythematosus

    Lupus, Vol. 18, Núm. 3, pp. 230-234

  3. STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk

    Annals of the Rheumatic Diseases, Vol. 68, Núm. 11, pp. 1746-1753

2007

  1. Structural insertion/deletion variation in IRF5 is associated with a risk haplotype and defines the precise IRF5 isoforms expressed in systemic lupus erythematosus

    Arthritis and Rheumatism, Vol. 56, Núm. 4, pp. 1234-1241